ArticleBlood2009

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.

Edmund A Rossi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.